六君子汤联合西药治疗慢性肺炎疗效及对患者肺功能的影响*

目的: 探讨六君子汤联合西药治疗慢性肺炎的疗效及对患者肺功能的影响。方法:选择慢性肺炎患者82例为研究对象。采用随机数字表分组法将其分为对照组和观察组，各41例。所有患者均给予吸氧、祛痰、止咳、纠正支气管扩张、维持水电解质以及酸碱度平衡等相关对症治疗。对照组根据痰培养结果选择合适的抗生素进行抗感染治疗，观察组在对照组基础上给予六君子汤治疗，比较两组治疗前、治疗3个疗程后肺功能、肺炎改善情况及其临床疗效。结果:治疗后1、2、3个月，两组患者中医症状积分均明显下降，且观察组比对照组下降更明显（P<0.05）。两组治疗前FVC、FEV1、FEV1%比较差异均无统计学意义（P>0.05）；两组治疗后FVC、FEV1、FEV1%水平均显著升高（P<0.05）；观察组治疗后FVC、FEV1、FEV1%水平均高于对照组（P<0.05）；两组治疗后WBC、CRP、肺炎指数和APACHEII评分均明显下降，且观察组比对照组更明显（P<0.05）。两组治疗前CD3+T、CD4+T、CD8+ T及CD4+T/CD8+ T比较差异无统计学意义（P>0.05）；两组治疗后CD3+T水平均无明显变化（P>0.05），CD4+T及CD4+T/CD8+ T水平均显著升高（P<0.05），CD8+ T水平显著降低（P<0.05）；观察组治疗后CD4+T及CD4+T/CD8+ T水平明显高于对照组（P<0.05），CD8+ T水平明显低于对照组（P<0.05）。两组治疗后生活质量评分显著升高，与治疗前比较差异有统计学意义（P<0.05）。随访12个月，两组复发率比较差异无统计学意义（P>0.05）。结论: 六君子汤联合西医治疗可显著改善慢性肺炎患者肺功能及肺炎情况，临床疗效确切。

Effect of Liujunzi decoction combined with western medicine on chronic pulmonary infection and its influence on lung function

Objective:To investigate the effect of Liujunzi decoction combined with western medicine on chronic pulmonary infection and its influence on lung function. Methods: 82 patients with chronic pulmonary infection admitted as the research subjects. They were divided into control group and observation group by random number table grouping method, 41 cases in each group. All patients were given oxygen inhalation, expectorant, cough, correction of bronchiectasis, maintenance of water and electrolyte and acid-base balance and other symptomatic treatment. The control group selected appropriate antibiotics for anti infection treatment according to the results of sputum culture. The observation group was treated with Liujunzi decoction on the basis of the control group. The improvement of lung function and pulmonary infection and its clinical effect were compared between the two groups before and after 3 courses of treatment. Results :After 1, 2, and 3 months of treatment, the scores of TCM symptoms in the two groups decreased significantly, and the observation group decreased more significantly than the control group (P< 0.05). There was no significant difference in FVC, FEV1 and FEV1% before treatment in the two groups (P>0.05), and the levels of FVC, FEV1 and FEV1% in the two groups were significantly higher (P<0.05) after treatment, and the levels of FVC, FEV1 and FEV1% in the observation group were higher than those of the control group (P<0.05), and the two groups were significantly decreased after treatment. And the observation group was more obvious than the control group (P<0.05). There was no significant difference between the two groups before the treatment of CD3+T, CD4+T, CD8+ T and CD4+T/CD8+ T (P>0.05), and there was no significant change in the level of CD3+T in the two groups (P>0.05). The average level of CD4+T and CD4+T/CD8+ T water was significantly higher. It was significantly higher than that in the control group (P<0.05), and the level of CD8+ T was significantly lower than that in the control group (P<0.05). The quality of life scores of the two groups increased significantly〖LM〗 after treatment, and the difference was statistically significant (P<0.05). Follow up for 12 months, there was no significant difference in recurrence rate between the two groups (P>0.05). Conclusion : Liujunzi decoction combined with western medicine can significantly improve the pulmonary function and pulmonary infection in patients with chronic pulmonary infection. It is effective in clinical treatment and can be used in the clinical treatment of chronic pulmonary infection.